Marshall Wace
CYTK icon

Marshall Wace’s Cytokinetics CYTK Stock Holding History

Marshall Wace’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.5M Sell
451,467
-205,141
-31% -$14.7M 0.03% 474
2026
Q1 		$43.3M Buy
656,608
+319,577
+95% +$20.3M 0.04% 418
2025
Q4 		$21.4M Buy
337,031
+158,051
+88% +$9.83M 0.02% 608
2025
Q3 		$9.84M Buy
178,980
+157,755
+743% +$6.5M 0.01% 923
2025
Q2 		$701K Sell
21,225
-2,007,567
-99% -$69.8M ﹤0.01% 2009
2025
Q1 		$81.5M Sell
2,028,792
-124,521
-6% -$5.72M 0.1% 173
2024
Q4 		$101M Buy
2,153,313
+279,612
+15% +$14.5M 0.12% 150
2024
Q3 		$98.9M Buy
1,873,701
+195,542
+12% +$10.9M 0.12% 146
2024
Q2 		$90.9M Sell
1,678,159
-878,644
-34% -$53M 0.12% 156
2024
Q1 		$179M Buy
2,556,803
+1,930,716
+308% +$149M 0.27% 65
2023
Q4 		$52.3M Sell
626,087
-907,882
-59% -$32.9M 0.09% 225
2023
Q3 		$45.2M Buy
1,533,969
+1,278,577
+501% +$42.6M 0.09% 227
2023
Q2 		$8.33M Sell
255,392
-489,915
-66% -$18.1M 0.02% 819
2023
Q1 		$26.2M Sell
745,307
-266,155
-26% -$10.9M 0.06% 368
2022
Q4 		$46.3M Buy
1,011,462
+55,576
+6% +$2.39M 0.1% 212
2022
Q3 		$46.3M Sell
955,886
-397,251
-29% -$19.1M 0.1% 217
2022
Q2 		$53.2M Buy
1,353,137
+1,322,232
+4,278% +$53.2M 0.11% 187
2022
Q1 		$1.14M Sell
30,905
-13,266
-30% -$471K ﹤0.01% 2392
2021
Q4 		$2.01M Buy
+44,171
New +$1.7M ﹤0.01% 2039
2021
Q3 		– Sell
-132,497
Closed -$2.62M – 3082
2021
Q2 		$2.62M Sell
132,497
-141,409
-52% -$3.32M 0.01% 1239
2021
Q1 		$6.37M Buy
273,906
+221,628
+424% +$4.73M 0.03% 693
2020
Q4 		$1.09M Sell
52,278
-155,175
-75% -$2.84M 0.01% 1180
2020
Q3 		$4.49M Buy
+207,453
New +$4.85M 0.03% 551
2019
Q2 		– Sell
-7,996
Closed -$65K – 1442
2019
Q1 		$65K Hold
7,996
– – ﹤0.01% 1498
2018
Q4 		$51K Buy
+7,996
New +$58.7K ﹤0.01% 1439
2018
Q2 		– Sell
-30,600
Closed -$220K – 727
2018
Q1 		$220K Buy
+30,600
New +$262K 0.01% 509

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace's CYTK Position: Q2 2026 in Review

Marshall Wace reduced its Cytokinetics (CYTK) stake by 31% in Q2 2026, selling an estimated $14.7M and leaving 451,467 shares worth $38.5M. The position accounts for 0.03% of the portfolio, ranked #474.

Marshall Wace first reported a position in CYTK in Q1 2018 and has held it in 26 quarters since. The position peaked at $179M in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Marshall Wace held 451,467 shares of Cytokinetics worth $38.5M as of Q2 2026.
  • Marshall Wace sold 205,141 Cytokinetics shares in Q2 2026, an estimated $14.7M.
  • Cytokinetics made up 0.03% of Marshall Wace's portfolio in Q2 2026, its #474 holding.
  • Marshall Wace first reported a position in Cytokinetics in Q1 2018 and has held it in 26 quarters since.
  • Marshall Wace's Cytokinetics position peaked at $179M in Q1 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.